Selected article for: "broad spectrum and host protein"
Author: Chan, Shiu-Wan
Title: Current and Future Direct-Acting Antivirals Against COVID-19
  • Cord-id: 2dgmsc2u
  • Document date: 2020_11_12
    • ID: 2dgmsc2u
    Snippet: The coronavirus disease of 2019 (COVID-19) has caused an unprecedented global crisis. The etiological agent is a new virus called the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). As of October, 2020 there have been 45.4 million confirmed cases with a mortality rate of 2.6% globally. With the lack of a vaccine and effective treatments, the race is on to find a cure for the virus infection using specific antivirals. The viral RNA-dependent RNA polymerase, proteases, spike protein-
    Document: The coronavirus disease of 2019 (COVID-19) has caused an unprecedented global crisis. The etiological agent is a new virus called the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). As of October, 2020 there have been 45.4 million confirmed cases with a mortality rate of 2.6% globally. With the lack of a vaccine and effective treatments, the race is on to find a cure for the virus infection using specific antivirals. The viral RNA-dependent RNA polymerase, proteases, spike protein-host angiotensin-converting enzyme 2 binding and fusion have presented as attractive targets for pan-coronavirus and broad spectrum direct-acting antivirals (DAAs). This review presents a perspective on current re-purposing treatments and future DAAs.

    Search related documents:
    Co phrase search for related documents
    • accessory protein and acute ards respiratory distress syndrome: 1
    • accessory protein and acute respiratory syndrome sars: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • accessory protein and adenosine triphosphate: 1, 2
    • acid contain and acute respiratory syndrome sars: 1, 2, 3
    • acidic endosome and action mode: 1
    • action mode and acute ards respiratory distress syndrome: 1
    • action mode and acute respiratory syndrome sars: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • action mode and ade antibody dependent enhancement: 1
    • action similar mode and acute respiratory syndrome sars: 1
    • active metabolite and acute ards respiratory distress syndrome: 1, 2, 3
    • active metabolite and acute respiratory syndrome sars: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • active site and acute ards respiratory distress syndrome: 1, 2
    • active site and acute respiratory syndrome sars: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and adenosine triphosphate: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and ade antibody dependent enhancement: 1, 2
    • acute ards respiratory distress syndrome and adenosine triphosphate: 1, 2
    • acute respiratory syndrome sars and ade antibody dependent enhancement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome sars and adenosine triphosphate: 1, 2, 3, 4, 5, 6, 7